Singleron Biotechnologies is an innovative and rapidly growing company providing complete solutions for single cell sequencing technologies. To improve clinical diagnosis, drug development, and health management, Singleron brings breakthrough single cell analysis techniques to clinicians and researchers.
Dr. Fang has over a decade of expertise in product development, commercialization, team management, and corporate strategy. She draws her expertise from previous roles as Deputy GM at Novogene and leading to the successful launch of 30+ products at QIAGEN. Recognitions: Forbes CN top 50 women.
As a seasoned biotech entrepreneur and former Proteona CEO, Dr. Schmidt brings a wealth of experience, having led AYOXXA Biosystems for 7 years. He served on boards of multiple biotech firms and provided advisory support to research institutes incl. EIT, Duke-NUS Medical School, SMART, and Scaler8.
With 20+ years in R&D Dr. Scolnick’s expertise spans academia and clinical services companies like Natera and Nugen Technologies. As the former Co-founder and CSO at Proteona, he led the development of wet and dry lab tools for single-cell tech. to predict patient responses to drugs.
Dr. Zhou has a decade of expertise in mechanical engineering, electronic technology, materials science, biotechnology, and stem cells. Before co-founding Singleron, she served as a Patent Agent at Dilworth IP LLC. She advised the CEO of IsoPlexis Inc. and was Associate Research Scientist at Yale.
Gao was senior manager in the audit and assurance section of Deloitte Touche Tohmatsu. Mr. Gao held various roles at Baixing Co., Ltd., including CFO and director. He also served as CFO of Frontage Holdings Group, successfully leading its IPO in 2019.
Dr. Fan served as CTO at IsoTex and worked as a Bioinformatician at Cellular Research Inc. and later as a Bioinformatics Manager at BD (Beckton Dickson Inc., USA).
Dr. Zi was Executive Director of Urology Laboratory at Shanghai Changhai Hospital, responsible for precision medicine research for prostate cancer. Dr. Zi is currently a member and secretary of the Medical Cell Biology Sub-Committee of Chinese Medical Association.
Dr. Buettner, a leading pathologist, has pioneered NGS and breakthrough technologies in clinical applications. He serves on the boards of LNS, Luxembourg, and the German Cancer Aid, and is the Founding President of the Vladimir Totovic Foundation/German Pathology.
Dr. Sun, an esteemed expert in Reproductive Biology and Medicine. Recognized for outstanding research, he received numerous awards, including the Canadian Fertility and Andrology Society Best Basic Science Research Paper (2004), and Chief scientist of National 973 program.
Dr. Koretzky is a globally recognized immunologist and significantly contributed to the understanding of immune system cell development. He holds fellowships with the American Academy of Arts and Sciences, American Association for the Advancement of Science.
Dr. Loeffert is a senior executive of the Life Sciences industry with more than 20 years of experience in product development and commercialization. Previously, he was Vice President of Product Development at QIAGEN, in charge of all product development activities of the Life Sciences Business Area.
Dr. Fan is an expert in cutting-edge single-cell micro/nano-technologies, investigating cellular heterogeneity and inter-cellular signaling networks in health and disease. He co-founded IsoPlexis, creator of IsoCode technology, ranked #1 in 2017 Top 10 Innovations.
Prior to joining Oriza Seed, Mr. Zhao had 14 years of experience in the pharmaceutical industry. Besides VC fund for early-stage companies, Mr. Zhao managed M&A investment funds of public company and PE fund. he was investor and board member of Ascentage Pharma, CSTONE Pharmaceuticals and others.
Yun Gao is VP with Lilly Asia Ventures. Prior to that, Yun was Investment Professional at Softbank China Venture Capital (SBCVC). She worked as Associate of Business Development and Corporate Strategy at Medtronic China and Senior Analyst at IMS Consulting Group.
Before establishing Sherpa Healthcare Partners in 2018, Mr. Ouyang played pivotal roles at Legend Group from 1992, serving as General Manager of Business Development and Business Unit Head of Lenovo. Joining Legend Capital in 2004 as Managing Director, he later founded its healthcare branch.
We are always looking for motivated and dedicated candidates. Check out our current open positions and reach out to us.